Fibrinolytic therapy for acute stroke: The Spanish experience

Cerebrovascular Diseases

Volumn 9, Issue SUPPL. 3, 1999, Pages 9-15

  Dávalos, Antoni ^a  

^a HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; STREPTOKINASE;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; FIBRINOLYTIC THERAPY; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPAIN; STROKE;

EID: 2442726736     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000047549     Document Type: Conference Paper

References (29)

1. Wardlaw JM, Warlow CP: Thrombolysis in acute ischemic stroke: Does it work? Stroke 1992;23:1826-1839.
2. Brott T: Thrombolysis for stroke. Arch Neurol 1996;53:1305-1306.
3. Riggs JE: Tissue-type plasminogen activator should not be used in acute ischemic stroke. Arch Neurol 1996;53:1306-1308.
4. Hachinski V: Thrombolysis in acute stroke. Arch Neurol 1996;53:1308.
5. Caplan LR, Mohr JP, Kistler JP, et al: Thrombolysis - Not a panacea for ischemic stroke. N Engl J Med 1997;337:1309-1310.
6. Grotta J: T-PA - The best current option for most patients. N Engl J Med 1997;337:1310-1312.
7. Multicenter Acute Stroke Trial-Italy (MAST-I) Group: Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995;346:1509-1514.
8. Multicenter Acute Stroke Trial-Europe Study Group: Fibrinolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996; 335:145-150.
9. Donnan GA, Davis SM, Chambers BR, et al: Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA 1996;276:961-966.
10. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
11. Hacke W, Kaste M, Fieschi C, Toni D, Lessafre E, von Kummer R, et al: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-1025.
12. Hacke W, Kaste M, Fieschi C, von Kummer R, Dávalos A, Meier D, et al, for the Second European-Australasian Acute Stroke Study Investigators: Randomised double-blind placebo-controlled trial of fibrinolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998;352:1245-1251.
13. Streiner TR, Bluhmki E, Kaste M, Toni D, Trouillas P, von Kummer R, Hacke W: The ECASS 3-hour cohort: Secondary analysis of ECASS data by time stratification. Cerebrovasc Dis 1998;8:198-203.
14. Wardlaw JM, Warlow CP, Counsell C: Systematic review of evidence on fibrinolytic therapy for acute ischaemic stroke. Lancet 1997;350: 607-614.
15. Ford G, Freemantle N: ECASS-II intravenous alteplase in acute ischemic stroke (letter). Lancet 1999;353:65-68.
16. Hacke W, Bluhmki E, Steiner T, Tatlisumak T, Mahagne MH, Sacchetti ML, Meier D, for the ECASS Study Group: Dichotomized efficacy end points and global end-point analysis applied to the EASS intention-to-treat data set. Post hoc analysis of ECASS I. Stroke 1998;29: 2073-2075.
17. Lees KR: ECASS-II intravenous alteplase in acute ischemic stroke (letter). Lancet 1999;353:65-68.
18. Bath P: Alteplase not yet proven for acute ischaemic stroke. Lancet 1998;352:1238-1239.
19. Raha S: ECASS-II intravenous alteplase in acute ischemic stroke (letter). Lancet 1999;353: 65-68.
20. Von Kummer R, Meier D, Hacke W, for the ECASS Group: Extent of ischemic lesion and hemorrhage in ECASS II (abstract). Stroke 1998;29:289.
21. Chiu D, Krieger D, Villar-Cordoba C, Kasner SE, Morgenstern LB, Bratina P, et al: Intravenous tissue plasminogen activator for acute ischemic stroke. Feasibility, safety, and efficacy in the first year of clinical practice. Stroke 1998;29:18-22.
22. Grond M, Stenzel C, Schmülling S, Rudolf J, Neveling M, Lechleuthner A, et al: Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke 1998; 29:1544-1549.
23. Hacke W, Dávalos A, von Kummer R, Kaste M, Larrue V: ECASS-II intravenous alteplase in acute ischemic stroke (letter). Lancet 1999; 353:65-68.
24. Langhorne P, Dennis M: Stroke Units: An Evidence-Based Approach. London, BMJ Books, 1998.
25. Dávalos A, Castillo J, Martinez-Vila E, for the Cerebrovascular Diseases Study Group of the Spanish Society of Neurology: Delay in neurological attention and stroke outcome. Stroke 1995;26:2233-2237.
26. Adams HP Jr, Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason CM, et al: Guidelines for fibrinolytic therapy for acute stroke: A supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1996;27:1711-1718.
27. Practice advisory: fibrinolytic therapy for acute ischemic stroke - summary statement: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1996;47:835-839.
28. Goldstein LB, Hey LA, Laney R: North Carolina stroke prevention and treatment facilities survey: rtPA therapy for acute stroke. Stroke 1998;29:2069-2072.
29. Alberts MJ, Chaturvedi S, Graham G, Hughes RL, Jamieson DG, Krakowski, F et al: Acute stroke teams: Results of a national survey. Stroke 1998;29:2318-2320.